PTV

PTV Logistics Announces Launch of PTV Developer OptiFlow API to Help Customers Reduce Costs and Emissions

Retrieved on: 
Tuesday, March 12, 2024
Algorithm, Transport, Senior, CO2, CSR, Catalog, API, ID, PTV, Fine chemical

KARLSRUHE, Germany, March 12, 2024 (GLOBE NEWSWIRE) -- PTV Logistics announces the official launch of the PTV Developer OptiFlow API.

Key Points: 
  • KARLSRUHE, Germany, March 12, 2024 (GLOBE NEWSWIRE) -- PTV Logistics announces the official launch of the PTV Developer OptiFlow API.
  • The PTV Developer OptiFlow API easily integrates with logistics operations, offering customers and partners unlimited, flexible options in building route optimization solutions to their exact specifications.
  • “This API signifies a major advancement in route optimization technology,” said Dr An de Wispelaere, Chief Product Officer, PTV Logistics.
  • We are looking forward to how things will develop further and teaming with PTV Logistics – now and in the future.”

WiSA Technologies Adds Additional Functionality to its Powerful WiSA E Immersive Audio Software

Retrieved on: 
Monday, March 25, 2024
Software, Mobile, Wireless, Entertainment, Hardware, Consumer Electronics, Technology, Other Manufacturing, Other Entertainment, TV and Radio, Audio, Video, Electronic Games, Manufacturing, Platin, Bang & Olufsen, SRC, DTS, ATMOS, Sport, CE, Name, WiSA, Electronics, TCL, Wireless speaker, Ecosystem, Music, Harman International, PTV, Video game

WiSA Technologies, Inc. (NASDAQ: WISA), a leading innovator in wireless audio technology for intelligent devices and next-generation home entertainment systems, announces the addition of two features to its WiSA E wireless immersive audio software stack.

Key Points: 
  • WiSA Technologies, Inc. (NASDAQ: WISA), a leading innovator in wireless audio technology for intelligent devices and next-generation home entertainment systems, announces the addition of two features to its WiSA E wireless immersive audio software stack.
  • WiSA Technologies, Inc. (NASDAQ: WISA) is a leading provider of immersive, wireless sound technology for intelligent devices and next-generation home entertainment systems.
  • WiSA Technologies, Inc. and the WiSA Technologies, Inc. logo are trademarks of WiSA Technologies, Inc.
  • The WiSA logo, WiSA®, WiSA Ready™, and WiSA Certified™ are trademarks and certification marks of WiSA, LLC.

30-Year Media Veteran Michele Ghee Joins Athlete Fan Owned media company PlayersTV as First-Ever Chairwoman Spearheading a Bold New Era in Athlete Media and Distribution

Retrieved on: 
Wednesday, March 27, 2024
Cloud, Cooking, BET Networks, Culture, African diaspora, Growth, Sport, Las Vegas Aces, WME, Entrepreneurship, History (American TV network), Advisory Council, WNBA All-Star Game, CNN, A&E, Black, Female, BET, Athlete, Chairperson, Thought, Investment, MLB, EBONY, AJ Andrews, Jet, Music, NBA, Basketball, Family, WNBA, NFL, Ghee, PTV

DALLAS, March 27, 2024 /PRNewswire/ -- PlayersTV, the first ever athlete owned media network and content provider dedicated to lifestyle and culture, proudly announces the appointment of Michele Ghee, CEO of Expectant Media, as its first Chairwoman of the Board. With an esteemed career spanning three decades in media and entertainment, Ghee's extensive expertise will drive innovation and growth for PlayersTV. Furthermore, PlayersTV is extremely excited to welcome WNBA stars Alysha Clark and Chiney Ogwumike as investor owners, reinforcing the network's commitment to diversity and excellence.

Key Points: 
  • With an esteemed career spanning three decades in media and entertainment, Ghee's extensive expertise will drive innovation and growth for PlayersTV.
  • As Chairwoman of PlayersTV, Ghee will steer the network's strategic direction, engaging athlete fans globally.
  • Her appointment marks a new era of growth and advancement for PlayersTV under her visionary leadership.
  • Ghee currently serves as CEO and Co-founder of Expectant Media, dedicated to supporting the growth of black-owned media.

Lytus Technologies Enters $326 Billion Data Center Market with Launch of Cutting-Edge Lytus Cloud Infrastructure Services

Retrieved on: 
Wednesday, March 6, 2024
Cloud, Transfer, PTV, Cloud computing, HPC, Natural language processing, Growth, BOT, Machine learning, Data, VPS, Video game

Ltd. (the “Company”) (Nasdaq:LYT), a leading global technology-driven services company, today announced the launch of Lytus Cloud, a cutting-edge suite of cloud infrastructure services with robust management capabilities.

Key Points: 
  • Ltd. (the “Company”) (Nasdaq:LYT), a leading global technology-driven services company, today announced the launch of Lytus Cloud, a cutting-edge suite of cloud infrastructure services with robust management capabilities.
  • Leveraging the Company’s in-house technological expertise and one of the most popular open-source cloud management platforms, Lytus Cloud is designed to meet the escalating demands of enterprise computing, tapping into the expansive US$325.9 billion global data center market (Statista) .
  • By offering a diverse array of cloud solutions, Lytus Technologies is set to provide a compelling alternative to traditional hyperscale cloud providers.
  • The introduction of Lytus Cloud is expected to catalyze growth across all Lytus Technologies' offerings, reducing cloud-related expenses and powering the deployment of state-of-the-art products and services.

Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

Retrieved on: 
Tuesday, February 27, 2024
MPS II, Hearing, ARIA, Antibody, LRRK2, PTV, IDS, Transferrin receptor, MAPT, Traffic barrier, ALS, Hunting, Dermatan sulfate, Therapy, BBB, SAN, Total, Amyloid-related imaging abnormalities, Alpha-synuclein, COMPASS, ETV, Hunter syndrome, Neurodegenerative disease, Conference, MPS, Safety, Biomarker, OTV, LUMA, AFL, SNCA, Amyloid beta, CSF, PIPE, Glycogen storage disease, Research, ATV, FDA, Food, Risk, Sanofi, UC, CD98, Patient, Cognition, Oligonucleotide, Science, Alfa, Pharmaceutical industry

Enrollment continues in the global Phase 2/3 COMPASS study and is expected to be completed in 2024.

Key Points: 
  • Enrollment continues in the global Phase 2/3 COMPASS study and is expected to be completed in 2024.
  • Sanofi intends to present the detailed efficacy and safety results of the ALS Phase 2 HIMALAYA study at a future scientific forum.
  • There was no collaboration revenue for the quarter ended December 31, 2023, compared to $10.3 million for the quarter ended December 31, 2022.
  • Further, for the quarter ended December 31, 2023, there was also a decrease in other unallocated research and development expenses as a result of reduced facility costs.

Lytus Technologies Holdings PTV. Ltd. announces 1 for 60 Reverse Stock Split

Retrieved on: 
Wednesday, February 21, 2024
Transfer, PTV, Registrar, British Virgin Islands, Corporate Affairs, Stock split, Security (finance)

Shareholders otherwise entitled to receive a fractional share as a result of the Reverse Split will receive a whole share in lieu of such factional share.

Key Points: 
  • Shareholders otherwise entitled to receive a fractional share as a result of the Reverse Split will receive a whole share in lieu of such factional share.
  • The Reverse Split will be effected by filing amendments with the Registrar of Corporate Affairs of the British Virgin Islands.
  • The Company is effecting the Reverse Split in order to maintain its listing on The Nasdaq Stock Market (“Nasdaq”).
  • We believe that the proposed Reverse Split will assist the Company in regaining compliance under the Nasdaq Listing Rules.

Denali Therapeutics Announces Key Anticipated 2024 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases

Retrieved on: 
Monday, January 8, 2024
CSF, Lysosomal storage disease, Cerebrospinal fluid, Risk, Sanfilippo syndrome, Amyloid, BBB, UC, Sanfilippo, Manuscript, ETV, ALS, OTV, SNCA, IDS, Asos, Conference, Cognition, RIPK1, Fluid mechanics, Neuroinflammation, Premedication, Glycogen storage disease, Amyloid beta, SGSH, Therapy, COMPASS, Traffic barrier, Hunting, N-sulfoglucosamine sulfohydrolase, Hunter syndrome, ISR, NewCo, Amyloid-related imaging abnormalities, Inflammation, CNS, Neurodegenerative disease, Takeda, Biomarker, Alpha-synuclein, K2, Biology, DSM-IV codes, LUMA, Brain, MPS, Investigational New Drug, PTV, ARIA, Nerve, AFL, Pathology, MPS II, Interim, BioRxiv, Plaque, MAPT, LRRK2, Elevator mechanic

The global Phase 2/3 COMPASS study continues to recruit up to 54 participants with neuronopathic and non-neuronopathic MPS II.

Key Points: 
  • The global Phase 2/3 COMPASS study continues to recruit up to 54 participants with neuronopathic and non-neuronopathic MPS II.
  • Upon completion of the ongoing Phase 1/2 study, and together with data from COMPASS, this combined data package is intended to support registration.
  • Increased RIPK1 activity in the CNS is hypothesized to drive neuroinflammation and cell necroptosis and to contribute to neurodegeneration.
  • Denali will maintain ownership of and continue to advance its current portfolio of clinical stage small molecule programs.

Denali Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights

Retrieved on: 
Tuesday, November 7, 2023
Neurofilament light polypeptide, MPS II, CLE, Biomarker, Therapy, MS, BioRxiv, ETV, Ulcerative colitis, BBB, ALS, PTV, ATV, ROFN, Definitive, Traffic barrier, Hunter syndrome, Phase 10, Denali, MPS, Antibody, Biology, Safety, Patient, AFL, Plaque, Fluid mechanics, ASO, ARIA, RIPK1, Asos, Research, Cerebrospinal fluid, ISR, SGSH, DSM-IV codes, Nerve, Brain, Society, Total, OTV, N-sulfoglucosamine sulfohydrolase, Hunting, LUMA, Glycogen storage disease, Manuscript, UC, CSF, Amyloid-related imaging abnormalities, Takeda, COMPASS, Pathology, CNS, Sanfilippo, Neuroinflammation, Collaboration, Multiple sclerosis, Sanfilippo syndrome, IDS, Cognition, Mutation, SAN, Pharmaceutical industry, Medical imaging, Fine chemical, Cryptocurrency, Biogen, LRRK2, Metabolism, Sanofi

SOUTH SAN FRANCISCO, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases, today reported financial results for the third quarter ended September 30, 2023, and provided business highlights.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases, today reported financial results for the third quarter ended September 30, 2023, and provided business highlights.
  • Denali has selected five ASO targets for further development and is focused on advancing two OTV candidates towards clinical development.
  • 2023 Guidance on Operating Expenses:
    Cash, cash equivalents, and marketable securities were approximately $1.12 billion as of September 30, 2023.
  • General and administrative expenses were $25.3 million and $23.3 million for the three months ended September 30, 2023 and 2022, respectively.

Lytus Technologies Receives Nasdaq Notification of Noncompliance with Audit Committee Requirements

Retrieved on: 
Wednesday, August 23, 2023
Biography, Audit committee, PTV, Notice

The Notice also states that NASDAQ will provide the Company a cure period in accordance with NASDAQ Listing Rule 5605(c)(4).

Key Points: 
  • The Notice also states that NASDAQ will provide the Company a cure period in accordance with NASDAQ Listing Rule 5605(c)(4).
  • The Company must also submit to Nasdaq documentation, including biographies of any new directors, evidencing compliance with the listing rule within the cure period.
  • The Company has remedied this issue by appointing a new director, Parvez Master, who meets the requirements of NASDAQ, to the Company's board of directors, audit committee and compensation committee.
  • In addition, the Company will submit Nasdaq documentation, including the biography of Mr. Master, evidencing compliance with the listing rule within the cure period.

Lytus Technologies enters Fintech space with the launch of a new payment gateway in India

Retrieved on: 
Monday, July 24, 2023
Digital divide, Fintech, Blockchain, Digital, Internet of things, POS, USD, Sale, PTV, IPTV, City, CFO, AI, Telecast, Cryptocurrency

Mumbai | New York, July 24, 2023 (GLOBE NEWSWIRE) --  Nasdaq-listed Lytus Technologies Holdings PTV. Ltd. (the “Company”) (NASDAQ: LYT), a leading global technology-driven services company, has announced the launch of its payments gateway for Indian consumers. This marks the entry of Lytus Technologies into the Indian fintech market through the introduction of its payments gateway offerings to businesses in the Indian cable and broadband sector.

Key Points: 
  • Ltd. (the “Company”) (NASDAQ: LYT), a leading global technology-driven services company, has announced the launch of its payments gateway for Indian consumers.
  • This marks the entry of Lytus Technologies into the Indian fintech market through the introduction of its payments gateway offerings to businesses in the Indian cable and broadband sector.
  • Initially, Lytus consumers using IPTV and broadband services will enjoy the convenience of the new payment gateway, facilitating their transactions.
  • Lytus Technologies' entry into the Indian fintech market with its innovative payments gateway marks an exciting milestone in the company's growth journey.